HRP20010584B1 - N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance - Google Patents

N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance

Info

Publication number
HRP20010584B1
HRP20010584B1 HR20010584A HRP20010584A HRP20010584B1 HR P20010584 B1 HRP20010584 B1 HR P20010584B1 HR 20010584 A HR20010584 A HR 20010584A HR P20010584 A HRP20010584 A HR P20010584A HR P20010584 B1 HRP20010584 B1 HR P20010584B1
Authority
HR
Croatia
Prior art keywords
piperidinyl
propoxy
pyridine
hydroxy
oxide
Prior art date
Application number
HR20010584A
Other languages
English (en)
Croatian (hr)
Inventor
Kuerthy Maria
Biro Katalin
Nagy Karoly
Ueroegdi Laszlo
Csakai Zita
Szilbereky Jenoe
Mogyoroesi Tamaes
Toeroek Magdolna
Komaeromi Andraes
Maervaenyos Ede
Barabaes Mihaely
Kardos Mihaelynee
Nagy Zoltan
Koraenyi Laeszloe
Nagy Melinda
Original Assignee
Cytrx Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytrx Corporation filed Critical Cytrx Corporation
Publication of HRP20010584A2 publication Critical patent/HRP20010584A2/hr
Publication of HRP20010584B1 publication Critical patent/HRP20010584B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HR20010584A 1999-02-26 2000-02-24 N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance HRP20010584B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9900475A HUP9900475D0 (en) 1999-02-26 1999-02-26 O-(3-piperidino-2-hydroxy-1-propyl)-hiyroximic acid-halogenid derivative, it's use for treating insulin resistance, and pharmaceutical compositions containing them as active component
PCT/HU2000/000015 WO2000050403A1 (en) 1999-02-26 2000-02-24 N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance

Publications (2)

Publication Number Publication Date
HRP20010584A2 HRP20010584A2 (en) 2002-08-31
HRP20010584B1 true HRP20010584B1 (en) 2010-08-31

Family

ID=90014224

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20010584A HRP20010584B1 (en) 1999-02-26 2000-02-24 N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance

Country Status (27)

Country Link
US (1) US6649628B1 (cs)
EP (1) EP1163224B1 (cs)
JP (1) JP4689838B2 (cs)
KR (1) KR100676124B1 (cs)
AT (1) ATE237590T1 (cs)
AU (1) AU779096B2 (cs)
BG (1) BG65178B1 (cs)
BR (1) BR0008969A (cs)
CA (1) CA2360451C (cs)
CZ (1) CZ297386B6 (cs)
DE (1) DE60002187T2 (cs)
DK (1) DK1163224T3 (cs)
EE (1) EE04961B1 (cs)
ES (1) ES2193055T3 (cs)
HR (1) HRP20010584B1 (cs)
HU (1) HUP9900475D0 (cs)
IL (2) IL144866A0 (cs)
NO (1) NO319793B1 (cs)
PL (1) PL197692B1 (cs)
PT (1) PT1163224E (cs)
RS (1) RS50083B (cs)
RU (1) RU2250901C2 (cs)
SI (1) SI1163224T1 (cs)
SK (1) SK287063B6 (cs)
UA (1) UA72495C2 (cs)
WO (1) WO2000050403A1 (cs)
ZA (1) ZA200106488B (cs)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0001583A2 (hu) * 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké
HU0103939D0 (en) * 2001-09-27 2001-11-28 Biorex Kutato Fejlesztoe Kft Pharmaceutical composition containing methformin and n-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride
US7384936B2 (en) 2002-01-11 2008-06-10 Cytrx Corporation Carboxamidine derivatives and their use in the treatment of vascular diseases
HUP0303584A3 (en) * 2003-10-30 2009-12-28 Cytrx Corp Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases
WO2008039514A1 (en) * 2006-09-26 2008-04-03 Cytrx Corporation Pharmaceutical compositions and methods for treating diseases associated with neurodegeneration
CN102123729B (zh) 2008-06-26 2015-04-29 奥菲泽米有限公司 Hsp70作为酶促活性调节物的应用
JP2010150243A (ja) 2008-11-18 2010-07-08 Santen Pharmaceut Co Ltd ピリジン−３−カルバルデヒドｏ−（ピペリジン−１−イル−プロピル）−オキシム誘導体を有効成分として含有する網脈絡膜変性疾患の治療剤
DK2646044T3 (da) 2010-11-30 2019-11-25 Orphazyme As Metoder til at øge den intracellulære aktivitet af Hsp70
HUP1100535A2 (en) 2011-09-26 2013-04-29 Bracelia Invest Ltd Pharmaceutical composition for enhancement of stem cell treatment
HUP1100534A2 (en) 2011-09-26 2013-04-29 Balazs Dr Hazay Pharmaceutical composition for the treatment of muscle atrophy
PL2892540T3 (pl) * 2012-09-06 2018-12-31 Mcpharma Biotech Inc. Leczenie biegunki i biegunki po odsadzeniu przy pomocy opornej skrobi ziemniaczanej
JP2016505194A (ja) 2012-09-14 2016-02-18 サン−ゴバン グラス フランスＳａｉｎｔ−Ｇｏｂａｉｎ Ｇｌａｓｓ Ｆｒａｎｃｅ 電気的な接続要素を備えるパネル
WO2015015248A1 (en) * 2013-07-30 2015-02-05 Debreceni Egyetem 67% The use of compounds showing heat shock protein (hsp) co-inducing properties to enhance the insulin sensitizing effect in the treatment of type 2 diabetes
KR102487452B1 (ko) 2014-09-15 2023-01-10 오르파짐 에이/에스 아리모클로몰 제제
US10898476B2 (en) 2016-04-13 2021-01-26 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
WO2017186919A1 (en) * 2016-04-29 2017-11-02 Orphazyme Aps Arimoclomol for treating glucocerebrosidase associated disorders
RU2019141123A (ru) 2017-05-24 2021-06-24 Орфазим А/С Индукторы белков теплового шока и лобно-височные нарушения
AU2019276048B2 (en) 2018-05-28 2025-09-04 Zevra Denmark A/S Hsp70 protein levels in PBMC samples as biomarker for disease
HUP1800298A1 (hu) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére
WO2021116487A1 (en) 2019-12-13 2021-06-17 Som Innovation Biotech, S.A. Compounds for use in the treatment of niemann-pick c disease
MX2023000033A (es) 2020-06-24 2023-04-10 Kempharm Denmark As Arimoclomol para tratar la enfermedad de gaucher.
IL303026A (en) 2020-11-19 2023-07-01 Zevra Denmark As Processes for preparing arimoclomol citrate and intermediates thereof
CN116783164A (zh) * 2020-11-19 2023-09-19 泽维拉丹麦股份有限公司 制备柠檬酸阿瑞洛莫及其中间体的方法
US20240115558A1 (en) 2020-12-24 2024-04-11 Zevra Denmark A/S Arimoclomol for the treatment of niemann pick disease, type c, in patients with er type missense mutations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990004584A1 (en) * 1988-10-20 1990-05-03 Biorex Kutató Fejleszto^' Kft. Novel o-(3-amino-2-hydroxypropyl)-hydroximic acid halides and process for preparing the same
WO1997016439A1 (en) * 1995-11-02 1997-05-09 Biorex Kutató és Fejlesztó Rt. Hydroxylamine derivatives useful for enhancing the molecular chaperon production and the preparation thereof
WO1998043948A1 (en) * 1997-04-03 1998-10-08 Biorex Kutató És Fejleszto^' Rt. Process for preparing o-(3-amino-2-hydroxy-propyl)-hydroxymic acid halides

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT78138A (hu) * 1995-12-22 2000-09-28 BIOREX Kutató és Fejlesztő Rt Hidroximsavszármazékot tartalmazó készítmény a növénytermesztés elősegítésére és alkalmazása
UA64716C2 (en) * 1996-08-09 2004-03-15 Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells
HUP0001583A2 (hu) * 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990004584A1 (en) * 1988-10-20 1990-05-03 Biorex Kutató Fejleszto^' Kft. Novel o-(3-amino-2-hydroxypropyl)-hydroximic acid halides and process for preparing the same
US5328906A (en) * 1988-10-20 1994-07-12 Biorex Kutato-Fejleszto Kft 0-(3-amino-2-hydroxypropyl)-hydroximic acid halides and process for preparing the same
WO1997016439A1 (en) * 1995-11-02 1997-05-09 Biorex Kutató és Fejlesztó Rt. Hydroxylamine derivatives useful for enhancing the molecular chaperon production and the preparation thereof
WO1998043948A1 (en) * 1997-04-03 1998-10-08 Biorex Kutató És Fejleszto^' Rt. Process for preparing o-(3-amino-2-hydroxy-propyl)-hydroxymic acid halides

Also Published As

Publication number Publication date
PL197692B1 (pl) 2008-04-30
DK1163224T3 (da) 2003-08-04
IL144866A0 (en) 2002-06-30
CA2360451A1 (en) 2000-08-31
IL144866A (en) 2007-07-04
SI1163224T1 (en) 2003-08-31
SK287063B6 (sk) 2009-10-07
UA72495C2 (uk) 2005-03-15
ATE237590T1 (de) 2003-05-15
BG105837A (en) 2002-03-29
NO20014103L (no) 2001-10-22
EE200100447A (et) 2002-12-16
NO20014103D0 (no) 2001-08-23
ZA200106488B (en) 2002-08-07
DE60002187D1 (de) 2003-05-22
JP2002537384A (ja) 2002-11-05
ES2193055T3 (es) 2003-11-01
PT1163224E (pt) 2003-07-31
NO319793B1 (no) 2005-09-12
HUP9900475D0 (en) 1999-04-28
BR0008969A (pt) 2001-11-27
RU2250901C2 (ru) 2005-04-27
EE04961B1 (et) 2008-02-15
AU3182400A (en) 2000-09-14
CZ20013053A3 (cs) 2002-01-16
JP4689838B2 (ja) 2011-05-25
HRP20010584A2 (en) 2002-08-31
US6649628B1 (en) 2003-11-18
KR20010102410A (ko) 2001-11-15
CZ297386B6 (cs) 2006-11-15
YU60301A (sh) 2004-05-12
EP1163224B1 (en) 2003-04-16
SK11582001A3 (sk) 2001-12-03
RS50083B (sr) 2009-01-22
EP1163224A1 (en) 2001-12-19
DE60002187T2 (de) 2003-12-11
BG65178B1 (bg) 2007-05-31
CA2360451C (en) 2011-01-04
KR100676124B1 (ko) 2007-01-31
WO2000050403A1 (en) 2000-08-31
PL350915A1 (en) 2003-02-10
AU779096B2 (en) 2005-01-06

Similar Documents

Publication Publication Date Title
HRP20010584B1 (en) N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance
DK1204654T3 (da) Benzofurylpiperaziner og benzofurylhomopiperaziner: Serotonin agonister
EA200300873A1 (ru) Новая соль сукцинат o-десметилвенлафаксина
TR200000129T2 (tr) Yepyeni spiroazabisiklik heterosiklik bileşikler.
AP1614A (en) New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents.
BG106586A (en) Pyrazolopyramidines as therapeutic agents
CO5031285A1 (es) Triarilimidazoles
GEP20053631B (en) ) New Spirotricyclic Derivatives and Their Use as Phosphodiesterase-7 Inhibitors
TW200407287A (en) A sulfonated amine acid derivative and the metalloproteinase inhibitor containing it (I)
ATE495187T1 (de) Dalda-analoge und ihre verwendung
HRP20020198B1 (hr) Formulacija moksifloksacina i kuhinjske soli
BR9814052B1 (pt) banho ácido de imersão de tetas à base de solução aquosa de clorito, com alto prazo de validade e proporcionando poder de sanitização e proteção dos tecidos.
ATE416157T1 (de) Inhibitoren von integrin alpha-v-beta-6
BR9913225A (pt) Novos agentes antibacterianos de isoxazolinona
MXPA02012076A (es) Compuestos quimicos.
TR200200263T2 (tr) Yeni seçiçi retinoid agonistleri
MXPA03002911A (es) Compuestos quimicos.
DE60205899D1 (en) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
MXPA02012659A (es) Derivados de pirazindiona condensados.
DE60025848D1 (en) Pyrimidin-derivate als selective inhibitoren von cox-2
GEP20043227B (en) 5HT1 Antagonists for Antidepressant Therapy
DE60121048D1 (de) PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE
BR0012751A (pt) Benzofuranos serotonérgicos
TR200001121T2 (tr) Antiromatizmal madde.
HRP20010885B1 (en) Ethanesulfonyl-piperidine derivatives

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
PPPP Transfer of rights

Owner name: CYTRX CORPORATION, US

ODRP Renewal fee for the maintenance of a patent

Payment date: 20100726

Year of fee payment: 8

B1PR Patent granted
PBON Lapse due to non-payment of renewal fee

Effective date: 20110225